CD274 and neoplasm: Importantly, studies have shown that immune checkpoint blockade (ICB) therapy with PD-L1 antibodies selectively protects T cells from decreased glucose utilization in the tumor microenvironment79, which suggests that ICB combined with IF may become a promising clinical tumor treatment strategy.